Premium
Lack of Interaction Between Cimetidine and Buspirone
Author(s) -
Gammans Richard E.,
Pfeffer Morris,
Westrick Mary L.,
Faulkner Harry C.,
Rehm Klaus D.,
Goodson Peter J.
Publication year - 1987
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1987.tb03521.x
Subject(s) - buspirone , cimetidine , pharmacokinetics , pharmacology , drug interaction , medicine , oral administration , agonist , receptor
Simultaneous administration of cimetidine and many benzodiazepine anxiolytics has resulted in decreased body clearance and marked prolongation of the half‐life of these agents. The pharmacokinetic interaction of buspirone, a new nonbenzodiazepine anxiolytic, and cimetidine was studied in 10 healthy male volunteers. Each received, in order, buspirone 45 mg/day (days 1–7), no drug (days 8–14), cimetidine 1 g/day (days 15–21), buspirone 45 mg/day plus cimetidine 1 g/day (days 22–28), and cimetidine 1 g/day (days 29–31). Buspirone and 1‐pyrimidinyl piperazine (1‐PP), an active metabolite, pharmacokinetics, urinary excretion of cimetidine, a manual dexterity test, the Stroop color‐word interference test, and a visual analog mood scale were evaluated on each treatment. There were no significant (p > 0.05) differences among treatments for any measurement except for a slight (31%) but significant (p < 0.05) increase in the 1‐PP C max value. These results suggest that within the normal therapeutic dosage ranges for both drugs, it is unlikely that a clinically significant interaction between them will occur.